Gland Pharma FY26 Annual Earnings Summary

Senexi's planned shutdown and operational losses persist; breakeven in Q3 depends on achieving €50M quarterly revenue.

Potential US tariffs on pharmaceutical imports could impact pricing and margins, though generics may be exempt. Management noted they would pass on costs to partners.

Synergia expects a lower Q2 due to summer shutdown, which could delay the path to sustained profitability.

The new 100M unit capacity may take time to fill, with meaningful utilization expected only from FY29-30, posing near-term underutilization risk.

Milestone revenue was lower at ₹44-45 crore vs normal run rate of ₹75 crore, impacting overall revenue growth.

While price erosion was flat this quarter, sustained competitive pricing could pressure margins in the base US business.

New 100M cartridge capacity may take 2+ years to fully utilize, with revenue dependent on partner approvals and market access.

Partner's US approval for liraglutide is delayed; additional data submitted in January 2026. If approval does not come through, revenue may be partially offset by European demand.

Existing lines are running at 80-90% utilization, with some at full capacity. New capacity additions are needed within 2 years to sustain growth.

US pricing declined 5-6% YoY, offset by cost efficiencies. Sustained pricing erosion could pressure margins if cost savings are not maintained.

Management noted potential 1-2% revenue impact from Middle East conflict-related logistics disruptions and glass cost inflation of 5-6%.

GLP-1 revenue not included in FY27 guidance due to uncertainty in partner approvals and market timing; ramp-up expected only post-2030.